Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.44 |
| ▸ | SOD3 | P08294 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 6/20 | 0.33 |
| ▸ | HTR2C | P28335 | 6/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20460995 | 0.90 | PDCD1 (0.36) | PDCD1CD274SOD3MAP4K1LRRK2 | |
| SCHEMBL27329663 | 0.85 | HTR2C (0.34) | PDCD1CD274MAP4K1HTR2AHTR2C | |
| SCHEMBL21017741 | 0.82 | PDCD1 (0.41) | PDCD1CD274SOD3HTR2AHTR2C | |
| SCHEMBL12307410 | 0.81 | PDCD1 (0.38) | PDCD1CD274SOD3MAP4K1 | |
| SCHEMBL14930383 | 0.77 | PDCD1 (0.50) | PDCD1CD274SOD3HTR2AHTR2C | |
| SCHEMBL30793495 | 0.74 | PDCD1 (0.35) | PDCD1CD274SOD3 | |
| SCHEMBL16221369 | 0.74 | PDCD1 (0.44) | PDCD1CD274SOD3HTR2AHTR2C | |
| SCHEMBL14925553 | 0.74 | PDCD1 (0.45) | PDCD1CD274SOD3HTR2AHTR2C | |
| SCHEMBL31739615 | 0.73 | PDCD1 (0.34) | PDCD1CD274SOD3HTR2AHTR2C | |
| SCHEMBL25410303 | 0.73 | BAZ2B (0.43) | PDCD1CD274SOD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3473624-B1 | NOVEL IMIDAZOPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) | 2022-05-11 | — | — | EP | disclosed |
| US-10870647-B2 | Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2020-12-22 | — | — | US | disclosed |
| US-20190315738-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2019-10-17 | — | — | US | disclosed |
| EP-3080103-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2018-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315738-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | FYN, SRC, LCK | PDCD1 869/4885CD274 3264/4885SOD3 3791/4885 |
| US-10870647-B2 | Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer | FYN, SRC, LCK | PDCD1 748/4885CD274 3040/4885SOD3 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.